[CP2] Interventions For Ultra-Rare Disorders (Urds) And The Logic Of Cost Effectiveness
2015 Value in Health
Schlander, M. | Garattini, S. | Holm, S. | Kolominsky-Rabas, P. | Marshall, D. A. | Nord, E. | Persson, U. | Postma, M. | Richardson, J. | Simoens, S. | de Sola-Morales, O. | Tolley, K. | Toumi, M. |
In many cases, medicines for ultra-rare disorders (URDs) have high acquisition costs and are associated with incremental cost per quality-adjusted life year (QALY) gained exceeding widely used benchmarks for cost effectiveness.